[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Omeros Corp (OMER)

Omeros Corp (OMER)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,244,126
  • Shares Outstanding, K 72,375
  • Annual Sales, $ 0 K
  • Annual Income, $ -3,350 K
  • EBIT $ -105 M
  • EBITDA $ -106 M
  • 60-Month Beta 2.54
  • Price/Sales 35.45
  • Price/Cash Flow 9.27
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 66.61% (-5.13%)
  • Historical Volatility 95.80%
  • IV Percentile 6%
  • IV Rank 5.01%
  • IV High 271.38% on 12/23/25
  • IV Low 55.81% on 02/13/26
  • Expected Move (DTE 6) 1.02 (5.93%)
  • Put/Call Vol Ratio 0.17
  • Today's Volume 5,902
  • Volume Avg (30-Day) 4,464
  • Put/Call OI Ratio 0.50
  • Today's Open Interest 100,935
  • Open Int (30-Day) 93,531
  • Expected Range 16.17 to 18.21

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.05
  • Number of Estimates 1
  • High Estimate $-0.05
  • Low Estimate $-0.05
  • Prior Year $-0.19
  • Growth Rate Est. (year over year) +73.68%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.12 +88.49%
on 07/17/26
18.14 -5.24%
on 08/13/26
+6.69 (+63.71%)
since 07/14/26
3-Month
6.70 +156.48%
on 06/12/26
18.14 -5.24%
on 08/13/26
+3.91 (+29.44%)
since 05/14/26
52-Week
3.94 +336.29%
on 09/17/25
18.14 -5.24%
on 08/13/26
+13.07 (+317.23%)
since 08/14/25

Most Recent Stories

More News
Stocks Rise Before the Open as Oil Prices Ease, U.S. PPI Data on Deck

September S&P 500 E-Mini futures (ESU26) are up +0.19%, and September Nasdaq 100 E-Mini futures (NQU26) are up +0.10% this morning, buoyed by a drop in oil prices, while investors await crucial U.S. producer...

META : 589.85 (-0.86%)
AMAT : 507.18 (-5.12%)
ADYEN.NA : 1,061.600 (+0.23%)
MAERB.C.DX : 20,480.000 (+7.00%)
CSCO : 111.68 (-1.58%)
FOSL : 5.57 (-0.18%)
SMCI : 39.84 (+1.74%)
NQU26 : 30,141.75s (-0.15%)
COHR : 325.83 (-0.43%)
OMER : 17.19 (-0.92%)
MSFT : 495.40 (-0.30%)
CRWV : 105.26 (-0.97%)
Omeros: Q2 Earnings Snapshot

Omeros: Q2 Earnings Snapshot

OMER : 17.19 (-0.92%)
Omeros Corporation Reports Second Quarter 2026 Financial Results

– Conference Call Today at 4:30 p.m. ET

OMER : 17.19 (-0.92%)
Omeros Corporation to Announce Second Quarter Financial Results on August 12, 2026

Omeros Corporation (NASDAQ: OMER) today announced that it will issue its financial results for the second quarter of 2026 on Wednesday, August 12, 2026 after market close. Omeros management will host a...

OMER : 17.19 (-0.92%)
CMS Grants New Technology Add-On Payment (NTAP) Status to YARTEMLEA®

--Provides additional Medicare reimbursement to hospitals and supports patient access for eligible Medicare patients with TA-TMA--

OMER : 17.19 (-0.92%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER

NEW YORK , July 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation ("Omeros" or the "Company") (NASDAQ: OMER).  Such investors are advised...

OMER : 17.19 (-0.92%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER

NEW YORK , July 23, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation ("Omeros" or the "Company") (NASDAQ: OMER).  Such investors are advised...

OMER : 17.19 (-0.92%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER

NEW YORK , July 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation ("Omeros" or the "Company") (NASDAQ: OMER). Such investors are advised...

OMER : 17.19 (-0.92%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER

NEW YORK , July 9, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation ("Omeros" or the "Company") (NASDAQ: OMER). Such investors are advised to...

OMER : 17.19 (-0.92%)
OMER Investors Have Opportunity to Join Omeros Corporation Fraud Investigation with the Schall Law Firm

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Omeros Corporation (“Omeros” or “the Company”) (NASDAQ:...

OMER : 17.19 (-0.92%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 80%. The market is in extreme overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM)...

See More

Key Turning Points

3rd Resistance Point 18.76
2nd Resistance Point 18.18
1st Resistance Point 17.69
Last Price 17.19
1st Support Level 16.62
2nd Support Level 16.04
3rd Support Level 15.55

See More

52-Week High 18.14
Last Price 17.19
Fibonacci 61.8% 12.72
Fibonacci 50% 11.04
Fibonacci 38.2% 9.36
52-Week Low 3.94

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.